Why haven't the authorities canceled Valenta Pharmaceuticals' license for Ingavirin and why isn't anyone warning of the dangers of using the drug? These questions remain unanswered in this material, where we will attempt to find out and identify those involved in the continued poisoning of Russians with harmful pills.
The article is very interesting. In the first half of 2020 alone, Russians purchased Ingavirin for nearly 6 billion rubles, resulting in an approximate annual income of 12 billion rubles for the manufacturer from this medicine alone.
Over a span of 25 years in the market
Valenta Pharmaceuticals' long history in the market undoubtedly provides a significant advantage for the business. In addition to Ingavirin, the company's main drugs include Grammidin, Trimedat, Teraligenn, Phenazepam, Pantocalcin, Aminazine, and others.
The pharmaceutical operations of Valenta bring substantial profits to its founders. In 2021, the owners received 5 billion rubles in profit, and the enterprise's profit in 2020 totaled 5.5 billion rubles, positioning Valenta among the top ten most profitable pharmaceutical businesses.
Officially, the founders of the company are JSC “Domestic Medicines”, but it's not possible to track the shareholders further as the trails lead to Cyprian offshores.
It's interesting to note that “Domestic Medicines” received almost ten times the profit in 2021 compared to 2020. This likely indicates that the profit may have simply been moved offshore to the business founders, possibly decreasing by around 10%, similar to Valenta PHARM.
Profit of JSC “Domestic Medicines”
And who resides in the Cyprus offshore?
In 2017, journalists revealed the detailed ownership structure of the offshore Lekarstva Holdings, and since then, the ownership structure has remained unchanged.
The primary shareholder of the company is businessman Kirill Syrov, who owns 22.1% of offshore shares. Kirill Syrov is a private individual, and little is known about his business activities apart from Valent FARM. He is married to singer Anna Pletneva.
Kirill Syrov with his wife
In April 2021, Syrov contracted a severe coronavirus infection and was hospitalized. It's curious why the owner of Valenta Pharm didn't take his essential drug Ingavirin. Perhaps he is also aware of its dangers.
In October 2021, Syrov was involved in a serious motorcycle accident, which resulted in multiple open fractures and lacerations, and he was admitted to intensive care. Despite this, he survived and made a full recovery.
Footage from an accident with Syrov
But let's delve a bit deeper. While Syrov owns the largest stake in the company and therefore reaps the greatest benefits from the business, the real decision-maker at “Valenta PHARM” is someone else, with a very small share in the business. This share, belonging to his mother Zinaida Reyhart, accounts for only 7%, but without this beneficiary – Dmitry Reyhart – Valenta FARM would not have achieved such success.
Reichart bought a share in Valenta Pharm in 2009. Before that, he had different roles in the Ministry of Health of the Russian Federation. In 2006, he became the head of the Federal Compulsory Medical Insurance Fund. 4 months after Reichart started, there were arrests. 11 FFOMS employees were arrested for taking bribes totaling 27 million rubles. But Reyhart was not affected. After 2 years, he left his position and went into business. Reyhart's connections helped the manufacturer of Ingavirin, Valenta Pharm, to have high sales and success among government agencies.
Dmitry Reyhart
coronavirus scandal
Experts doubted the therapeutic function of Ingavirin because until 2014, another drug called Dicarbamine with the same active substance was produced. In 2014, Valenta Pharm requested the Ministry of Health to revoke the license of the drug. The reason for this move is unknown.
Based on this letter, the Ministry of Health canceled the registration of the drug on May 12, 2014.
Letter of Cancellation of Dicarbamine Registration
Years later, Ingavirin, a drug with a similar formulation, appeared and was included in the list of vital and essential drugs. One substance for cancer and SARS. It seems suspicious even to a non-doctor.
Until 2020, no one remembered this situation until the coronavirus epidemic. At the end of 2020, Valenta Pharm began testing Ingavirin on volunteers as a cure for Covid. By Government Decree No. 441 of 04/03/2021, the manufacturer was allowed to complete the test ahead of schedule and release Ingavirin for free sale.
But Valenta Pharm was not concerned about regulations. In January 2020, Ingavirin was advertised as a medicine against coronavirus, even though it was not officially approved in Russia yet. Money was the priority. The Department for Control of Advertising and Unfair Competition of the Federal Antimonopoly Service of Russia found violations in the advertisement, but no action was taken. It is unclear how Ingavirin became the main medicine against the coronavirus pandemic.
global purge
Anti-advertising is also advertising. In the case of Ingavirin and Valenta Pharm, this rule does not apply. It's unlikely to make billions from a drug against a virus that can cause leukemia.
So, Valenta doesn't mind removing materials about the dangers of the drug. They prefer to pay fees to the authors of investigations about Ingavirin to remove materials about its dangers, instead of going through the courts. As a result, publications about Ingavirin have disappeared from several websites, VKontakte pages, and YouTube channels.
If Valenta PHARM has nothing to hide, why can’t pharmacists answer journalists’ questions and try in every possible way to hide any information about their flagship drug. Obviously, the case is not clean, and they have something to hide.
